肉毒毒素:一种潜在的心血管病原体?
Lauren E Williams1, William H Frishman2
1From the Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiology in review
|October 27, 2023
概括
肉毒神经毒素 (BoNT) 作为一种心血管药物具有前景,研究探讨了其对高血压和心力衰竭等疾病的安全性和有效性. 需要进一步的研究来确认其在心脏病学中的治疗潜力.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肉毒神经毒素 (BoNT) 在医药和化品中广泛使用.
- 它以其在各种临床应用中的安全性和耐受性而闻名.
- 新兴研究表明,潜在的心血管益处.
研究的目的:
- 审查目前关于肉毒神经毒素 (BoNT) 作为心血管治疗剂的潜在证据.
- 突出正在进行的研究和临床试验,调查心血管疾病的BoNT.
主要方法:
- 在心血管应用中对BoNT进行现有临床前和临床研究的审查.
- 从先前的调查和正在进行的试验中分析安全性和有效性数据.
主要成果:
- 肉毒神经毒素 (BoNT) 已在治疗缺血-再输损伤,高血压,心房动和心力衰竭方面证明了安全性和潜在的有效性.
- 目前的试验正在探索这些心血管应用.
结论:
- 肉毒神经毒素 (BoNT) 是新型心血管治疗的潜在候选者.
- 需要进一步的人体研究以增强统计能力来确定其有效性并指导临床采用.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
685
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
685
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
432
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
432
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
867
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
867
Antianginal Drugs: Nitrates and β-Blockers
608
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
608
Drugs Acting on Autonomic Ganglia: Blockers
1.0K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.0K


